Newegg Commerce Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Newegg Commerce Inc trades at $11.69 (market cap $243.30M), while Vertex Pharmaceuticals Incorporated trades at $508.7 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 524.2× Newegg Commerce Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Newegg Commerce Inc for 14 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| NEGG | VRTX | |
|---|---|---|
Market Cap | $243.30M | $127.55B |
Volume | 41,252 | 1,487,944 |
Sector | Consumer Cyclical | Health |
52-Week High | $92.74 | $557.96 |
52-Week Low | $11.49 | $407.37 |
Typical Hold Time | 14 Days | 120 Days |
Enterprise Value | $213.53M | $121.68B |
Signals from Pluang's Aura AI — not financial advice
NEGG stock trades at $12.01, up 0.84% today, but technical indicators are bearish with moving averages signaling a downtrend. The company shows improving fundamentals, with revenue of $1.44B in 2025 and a net income margin turning positive to 0.68% in 2026 projections. Recent news highlights partnerships with Western Digital and Hewlett Packard Enterprise to support IT infrastructure, though insider selling has created negative sentiment.
The outlook is mixed; earnings beats and margin improvement offer upside, but the stock faces bearish technicals and a consensus price target of $7.75 below the current price. Key risks include volatile cash flows and high liabilities, while a single analyst rates it Buy. Investors should weigh operational progress against valuation concerns and market sentiment.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →